Dr. Sabrina Paganoni, Massachusetts General Hospital, will discuss CENTAUR, a trial for people with ALS. CENTAUR ("Combination of Phenylbutyrate and Tauroursodeoxycholic Acid") is a Phase 2 trial testing the efficacy and safety of AMX0035 for the treatment of ALS as well as its impact on several disease biomarkers. CENTAUR is expected to enroll 132 participants nationwide.
In partnership with The ALS Association, NEALS offers live webinars for people with ALS, caregivers and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. Our webinars also offer participants the opportunity to ask questions directly of the experts running clinical trials and conducting research activities.